Hewlett-Packard is only one of countless partnerships that keep business and innovation thriving. From small-cap companies to industry behemoths, no single entity is too large or too small to benefit from strategic collaborations.
Development-stage biotech company Advaxis knows this strategy well and has established a large portfolio of advantageous partnerships. Advaxis is focused on developing immunotherapies for cancer and infectious disease. The company has forged partnerships with numerous biotech alliances, resulting in the issuance of 41 patents issued and 34 patents pending. Partnerships include:
National Cancer Institute Gynecologic Oncology Group
Advaxis is collaborating with the GOG to conduct a multi-center, Phase 2 clinical trial of ADXS-HPV, a Lm-LLO based immunotherapy targeted to HPV, in patients with recurrent or refractory cervical cancer who have failed prior cytotoxic therapy.
University of Pennsylvania School of Veterinary Medicine
Advaxis is collaborating with Dr. Nicola Mason at the University of Pennsylvania School of Veterinary Medicine to study the ADXS-cHER2 construct for the treatment of canine osteosarcoma in large breed companion dogs.
Cancer Research UK
Cancer Research UK (CRUK), the UK organization dedicated to cancer research, is conducting a clinical trial to investigate the use of ADXS-HPV, a Lm-LLO based immunotherapy targeted to HPV, for the treatment of head and neck cancer. This Phase 1/2 clinical trial will investigate the safety and efficacy of ADXS-HPV in head and neck cancer patients who have previously failed treatment with surgery, radiotherapy and chemotherapy – alone or in combination. The study is to be conducted at 3 sites in the UK (Aintree Hospital at the University of Liverpool, The Royal Marsden Hospital in London, and Cardiff Hospital at the University of Wales).
Brown University Oncology Group
Brown University Oncology Group (BrUOG) will be coordinating a Phase 1/2 study of ADXS-HPV in 25 patients with HPV-associated anal cancer. This study will evaluate the safety and effectiveness of ADXS-HPV when combined with standard chemotherapy and radiation treatment for anal cancer.
National Cancer Institute Vaccine Section
Advaxis has a Collaborative Research and Development Agreement (CRADA) with the Vaccine Section of the National Cancer Institute for the development of Advaxis immunotherapies. The work is intended to enhance the anti-tumor effects of Advaxis immunotherapies and alter the tumor microenvironment, enabling them to be used with other methods of cancer treatment.
Wistar Institute
Advaxis is collaborating with the Wistar Institute to explore the potential of FAP as a target for immune attack and as the basis for the development of an Advaxis immunotherapy. Therapeutically targeting FAP (fibroblast activation protein) might significantly reduce tumor growth, as it has in some mouse studies.
University of British Columbia
Advaxis is collaborating with the laboratory of Dr. Tobias Kollmann at the University of British Columbia to develop Advaxis immunotherapies for the treatment of infectious disease and to develop new dosage forms. Dr. Kollmann will use Advaxis’ proprietary immunotherapy vectors for the development of novel infectious disease applications.
Karolinska Institutet
Advaxis is collaborating with the laboratory of Professor Marianne van Hage at the Karolinska Intitutet in Stockholm, Sweden, to evaluate the potential of Advaxis’ immunotherapies to treat and prevent allergies in established scientific models of allergic diseases.
For more information, visit www.Advaxis.com
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
